Advicenne Secures Financial Stability with Extended Runway to 2028

On October 12, 2026, Advicenne, a pharmaceutical company focused on rare kidney disease treatments, announced the extension of its financial runway to 2028. This milestone follows the receipt of €1 million, finalizing a bond financing agreement with L1 Capital. As of June 30, 2026, this funding has bolstered Advicenne's cash position from €1.55 million, providing significant financial security.

This financial extension is attributed to successful sales of key products, Likozam® and Levidcen®, alongside disciplined company resource management. CEO Didier Laurens highlighted that this funding supports financial needs amidst unstable markets, simultaneously leveraging strong operational performance to enhance financial outlooks.

Additionally, Advicenne can access €1.2 million more in financing through its major shareholder, Cemag Invest, and other partners. This financial maneuver aims to mitigate risks and sustain growth, but potential dilution of shares remains a consideration.